Stryker: COVID Delays And Digital Communications

Jan. 23, 2022 8:49 PM ETStryker Corporation (SYK) StockSYK3 Comments
Keith Williams
8.79K Followers

Summary

  • Up to ~30% of Stryker’s customers have elective issues; however, the underlying diseases are progressive so they delay rather than stop acquiring Stryker’s products.
  • COVID notwithstanding, Stryker remains in a strong financial position.
  • Stryker has a long record of successful growth by acquisition as is evidenced by the recent announcement of the acquisition of Vocera Communications.
  • Long-term prospects for Stryker seem good, but the Omicron variant is leading to a near-term pullback.
Stryker sign and logo at medical technologies firm Stryker Corporation headquarters

Michael Vi/iStock Editorial via Getty Images

A defining feature of Stryker (NYSE:SYK) has been its ability to not only see emerging opportunities to expand its business reach, but also to acquire companies leading the charge so it can bring to its business new definition. I’ve

This article was written by

8.79K Followers
Keith began his career as a research scientist (developmental biology, biochemistry, molecular biology) at the Australian National University, University of Oxford (UK), the Max Planck Institute for Biochemistry (Munich, Germany) and finally Macquarie University (Sydney) where he held a Chair in Biology and established the Centre for Analytical Biotechnology. Pioneering the area of proteomics (with Marc Wilkins in his group coining the term), Keith established the world’s first government-funded Major National Proteomics Facility (Australian Proteome Analysis Facility) which was involved with industrialising protein science. Keith left academe with his team to found Proteome Systems Ltd in 1999 to commercialise proteomics. The company had a strong focus on intellectual property, engineering/technology and bioinformatics. As CEO he led the company to ASX listing in 2004. Since 2005 Keith has been involved in new business development in biotech, e-health and other emerging technologies. Keith sees climate change and sustainable development as a major issue for humankind and also a major business disruptor/risk and opportunity. Keith holds a Bachelor Agr Science from the University of Melbourne and a PhD from the Australian National University. He is a Fellow of the Australian Academy of Technological Sciences & Engineering and received an AM (Member of the Order of Australia) for services to the Biotechnology Industry. He has received various industry awards including an Innovation Hero Medal from the Warren Centre for Advanced Engineering. With 300 scientific papers and many patents written, Keith has a clear view of innovation in the Biotechnology and Climate/Renewable Energy space. He is not a financial advisor but his perspective adds relevance to decision-making concerning feasibility and investment in technology innovation.

Analyst’s Disclosure:I/we have a beneficial long position in the shares of ENPH, BYDDF, VWDRY either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

About SYK Stock

SymbolLast Price% Chg
Market Cap
PE
Yield
Rev Growth (YoY)
Short Interest
Prev. Close
Compare to Peers

More on SYK

Related Stocks

SymbolLast Price% Chg
SYK
--